医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cogstate Announces First U.S. Deployment of the Cognigram™ System at the University of Notre Dame

2017年10月11日 PM09:00
このエントリーをはてなブックマークに追加


 

BOSTON

The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in the U.S.

“We are thrilled that the University of Notre Dame decided to adopt our cognitive testing solution immediately after the Cognigram system became available in the U.S.,” said Frank Cheng, President of Cogstate Healthcare. “We look forward to supporting the University of Notre Dame in their concussion management programs for RecSports.”

The Cognigram system is a digital cognitive assessment tool with self-administered assessment that can be completed both in-clinic and at-home. It is for prescription use, and is intended to aid healthcare professionals with an objective measurement of cognition for use in individuals aged 6 – 99 years old. The Cognigram system can be used to assess cognition on a single occasion or cognitive change over periodic assessments. Performance on the Cognigram system is unaffected by language, education, cultural background, or repeat practice.

Factors that may affect an individual’s cognition include the presence of mild cognitive impairment (MCI), Alzheimer’s disease, concussion, head injury, major depressive disorder, HIV related dementia, schizophrenia, attention deficit hyperactivity disorder (ADHD), multiple sclerosis, Parkinson’s disease, the effects of medication or surgery, as well as a variety of psychological states (e.g. stress, fatigue).

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading science and technology solutions provider dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and is a pioneer in commercializing rapid, reliable and sensitive computerized cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; elite sporting organizations and military; physicians and patients; renowned academic institutions and public-private partnerships. For more information visit www.cogstate.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171011005290/en/

CONTACT

Media:
Cogstate Healthcare
Frank Cheng, +1 203-461-0699
President
fcheng@cogstate.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange
  • 武田获得CHMP肯定意见,接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者
  • 富士制药向Alvotech投资5000万美元
  • 武田薬品、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者を治療するためのアドセトリス(ブレンツキシマブ・ベドチン)とAVDの併用に関するCHMPの肯定的見解を受領
  • AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit